1
|
Gibson J, Baird T, Pandey S, Tolson C, Coulter C, Eather G, Thomson R. The clinical significance of Mycobacterium triplex. Respir Med 2019; 159:105808. [PMID: 31731086 DOI: 10.1016/j.rmed.2019.105808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2019] [Revised: 09/08/2019] [Accepted: 11/01/2019] [Indexed: 11/19/2022]
Abstract
OBJECTIVES Mycobacterium triplex is a slow-growing nontuberculous mycobacteria (NTM) and is a rare cause of human disease. The pathogenicity, natural history and spectrum of disease is unknown. The aim of this study was to review the clinical features, outcomes and drug susceptibility testing (DST) of all M. triplex isolates in Queensland, Australia to guide management of this rare NTM infection in the future. METHODS This retrospective study included all patients who isolated M. triplex in Queensland, Australia from the 1st January 2000 to 31st December 2016. Clinical information was obtained from medical records to determine the clinical significance of isolates, natural history of disease and treatment outcomes. DST was performed on 15 isolates. RESULTS Forty-three patients (21 male) had positive cultures for M. triplex. Thirty-nine patients had isolates from pulmonary specimens and 17 (43.6%) met the American Thoracic Society criteria for NTM lung disease. Six patients with pulmonary infection received antimicrobial therapy with 5 patients demonstrating treatment success. Four patients had localised extrapulmonary disease and were cured with surgical management ± antimicrobial therapy. DST suggests 93% of isolates are susceptible to macrolides. CONCLUSION This is the largest case series of M. triplex isolates and confirms it is a rare human pathogen. Extrapulmonary disease responded well to surgical management. Treatment of M. triplex pulmonary disease is challenging, and the optimal antimicrobial regimen is unknown. However, the DST data suggests macrolide resistance is rare and macrolides should be included in treatment regimens.
Collapse
Affiliation(s)
- Justine Gibson
- Princess Alexandra Hospital, Brisbane, Queensland, Australia; Metro South Clinical Tuberculosis Service, Brisbane, Queensland, Australia.
| | - Tim Baird
- Sunshine Coast University Hospital, Queensland, Australia
| | - Sushil Pandey
- Queensland Mycobacterium Reference Laboratory (QMRL), Pathology Queensland, Brisbane, Australia
| | - Carla Tolson
- Queensland Mycobacterium Reference Laboratory (QMRL), Pathology Queensland, Brisbane, Australia
| | - Chris Coulter
- Metro South Clinical Tuberculosis Service, Brisbane, Queensland, Australia; Queensland Mycobacterium Reference Laboratory (QMRL), Pathology Queensland, Brisbane, Australia
| | - Geoffrey Eather
- Princess Alexandra Hospital, Brisbane, Queensland, Australia; Metro South Clinical Tuberculosis Service, Brisbane, Queensland, Australia
| | - Rachel Thomson
- Metro South Clinical Tuberculosis Service, Brisbane, Queensland, Australia; University of Queensland, Brisbane, Queensland, Australia; Gallipoli Medical Research Institute, Brisbane, Queensland, Australia; Greenslopes Private Hospital, Brisbane, Queensland, Australia
| |
Collapse
|
2
|
Shirata M, Tamaru A, Marumo S, Fukui M. Mycobacterium triplex pulmonary disease in an immunocompetent host: A case report and literature review. IDCases 2019; 18:e00648. [PMID: 31720222 PMCID: PMC6838927 DOI: 10.1016/j.idcr.2019.e00648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2019] [Revised: 09/24/2019] [Accepted: 09/24/2019] [Indexed: 11/17/2022] Open
Abstract
The report describes a rare case of pulmonary disease due to M. triplex. The pulmonary lesion was discovered as an incidental finding on chest X-ray. The organism was identified by housekeeping gene sequencing analysis. The patient had a history of tuberculosis & non-tuberculous mycobacterial infection. The patient was treated with antimicrobials and the lesion was cured.
Mycobacterium triplex (M. triplex) is a bacterial species that can cause severe pulmonary diseases. Despite its clinical importance, only a few cases of M. triplex infection have been reported. Here, we present a rare case of pulmonary disease due to M. triplex in an immunocompetent patient who showed abnormal findings on chest X-ray and computed tomography scans. In this patient, the bacterium was identified by DNA sequencing analysis of the 16S rRNA and hsp65 genes. The patient was successfully treated with the appropriate antimicrobial agents. To put this case into the context of the current literature, we also reviewed other case reports of M. triplex infection.
Collapse
Affiliation(s)
- Masahiro Shirata
- Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
- Corresponding author.
| | - Aki Tamaru
- Division of Microbiology, Bacteriology Section, Osaka Institute of Public Health, 1-3-69 Nakamichi, Higashinari-ku, Osaka 537-0025, Japan
| | - Satoshi Marumo
- Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
| | - Motonari Fukui
- Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
| |
Collapse
|
3
|
Matsuda S, Suzuki S, Morimoto K, Aono A, Nishio K, Asakura T, Sasaki Y, Namkoong H, Nishimura T, Ogata H, Hasegawa N, Kurashima A, Ishii M, Tatsumi K, Mitarai S, Goto H. Mycobacterium triplex pulmonary disease with acquired macrolide resistance in immunocompetent patients. Clin Microbiol Infect 2018; 24:671-672. [PMID: 29309938 DOI: 10.1016/j.cmi.2017.12.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 12/25/2017] [Accepted: 12/26/2017] [Indexed: 11/26/2022]
Affiliation(s)
- S Matsuda
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - S Suzuki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - K Morimoto
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan; Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
| | - A Aono
- Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - K Nishio
- Department of Respiratory Medicine, Kawasaki Municipal Ida Hospital, Kanagawa, Japan
| | - T Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Y Sasaki
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - H Namkoong
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - T Nishimura
- Health Centre, Keio University, Tokyo, Japan
| | - H Ogata
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - N Hasegawa
- Centre for Infectious Diseases and Infection Control, Keio University School of Medicine, Tokyo, Japan
| | - A Kurashima
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - M Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - K Tatsumi
- Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - S Mitarai
- Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - H Goto
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| |
Collapse
|
4
|
Yoo DK, Hosseini-Moghaddam SM. Pacemaker pocket infection due to Mycobacterium goodii, a rapidly growing mycobacteria. BMJ Case Rep 2017; 2017:bcr-2016-218323. [PMID: 28073877 DOI: 10.1136/bcr-2016-218323] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
A woman aged 74 years with an implanted dual-chamber pacemaker presented with pacemaker site infection after failing empiric antimicrobial therapy. The pathogen was later identified as Mycobacterium goodii, a rapidly growing mycobacteria species. The pacemaker was subsequently removed and the patient was treated with oral ciprofloxacin and doxycycline with clinical improvement. In this article, we describe a rare case of pacemaker site infection by M. goodii.
Collapse
Affiliation(s)
- David K Yoo
- Department of Medicine, Western University, Schulich School of Medicine and Dentistry, London, Ontario, Canada
| | | |
Collapse
|
5
|
First detection of Mycobacterium triplex in Latin America. Int J Mycobacteriol 2015; 5:89-91. [PMID: 26927996 DOI: 10.1016/j.ijmyco.2015.09.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 09/02/2015] [Indexed: 11/23/2022] Open
Abstract
In this study we describe the first isolation of Mycobacterium triplex in Latin America. This species causes infections in humans, with very few reports from around the world. We isolated two sputum specimens of a patient with a 6-year history of human immunodeficiency and tuberculosis treatment failure. All tests used confirmed M. triplex and the patient responded well to drug therapy for 18months.
Collapse
|
6
|
Caruso G, Angotti R, Molinaro F, Benicchi E, Cerchia E, Messina M. Cervical Lymphadenitis by Mycobacterium triplex in an Immunocompetent Child: Case Report and Review. Indian J Microbiol 2014; 53:241-4. [PMID: 24426116 DOI: 10.1007/s12088-013-0367-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Accepted: 01/29/2013] [Indexed: 11/26/2022] Open
Abstract
Mycobacterium triplex was first described in 1996. This nontuberculous Mycobacterium causes a severe pulmonary disease in immunocompromised patients but it can involve also healthy patients. A literature search was made on the PubMed database and it produced only few cases of children with cervical lymphadenitis due to this Mycobacterium Triplex. We are describing a case of M. triplex cervical lymphadenitis in an immunocompetent child.
Collapse
Affiliation(s)
- G Caruso
- ENT Unit, University of Siena, 53100 Siena, Italy
| | - R Angotti
- Division of Pediatric Surgery, Department of Medical, Surgical and Neurological Sciences, University of Siena, Policlinico "Le Scotte" Viale Bracci 16, 53100 Siena, Italy
| | - F Molinaro
- Division of Pediatric Surgery, Department of Medical, Surgical and Neurological Sciences, University of Siena, Policlinico "Le Scotte" Viale Bracci 16, 53100 Siena, Italy
| | - E Benicchi
- ENT Unit, University of Siena, 53100 Siena, Italy
| | - E Cerchia
- Division of Pediatric Surgery, Department of Medical, Surgical and Neurological Sciences, University of Siena, Policlinico "Le Scotte" Viale Bracci 16, 53100 Siena, Italy
| | - M Messina
- Division of Pediatric Surgery, Department of Medical, Surgical and Neurological Sciences, University of Siena, Policlinico "Le Scotte" Viale Bracci 16, 53100 Siena, Italy
| |
Collapse
|
7
|
van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012; 39:173-6. [DOI: 10.1016/j.ijantimicag.2011.09.019] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Revised: 09/20/2011] [Accepted: 09/21/2011] [Indexed: 11/25/2022]
|
8
|
|
9
|
de Lisle GW, Pamela Kawakami R, Yates GF, Collins DM. Isolation of Mycobacterium bovis and other mycobacterial species from ferrets and stoats. Vet Microbiol 2008; 132:402-7. [DOI: 10.1016/j.vetmic.2008.05.022] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2008] [Revised: 05/23/2008] [Accepted: 05/26/2008] [Indexed: 11/29/2022]
|